Results 71 to 80 of about 33,368 (159)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin

Viruses, 2012
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C.
Osamu Yokosuka, Fumio Imazeki, Makoto Arai, Keiichi Fujiwara, Xia Jiang, Shuang Wu, Shingo Nakamoto, Tatsuo Kanda, Tatsuo Miyamura   +8 more
doaj   +1 more source

Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis

International Journal of Infectious Diseases, 2019
Objectives: Lassa fever (LF) causes annual outbreaks in endemic regions with high mortality of symptomatic patients. Ribavirin is recommended as standard treatment for LF in national and international guidelines but the evidence base for this ...
Kirsten Alexandra Eberhardt, Johannes Mischlinger, Sabine Jordan, Mirjam Groger, Stephan Günther, Michael Ramharter   +5 more
doaj   +1 more source

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus

CPT: Pharmacometrics & Systems Pharmacology, 2016
Ribavirin remains an important component of hepatitis C treatment in certain clinical scenarios, but it causes hemolytic anemia. A quantitative understanding of the ribavirin exposure‐anemia relationship is important in dose individualization ...
LS Wu, LC Jimmerson, CE MacBrayne, JJ Kiser, DZ D'Argenio   +4 more
doaj   +1 more source

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

BMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed, Hafiz Ghulam Murtaza Saleem, Sajjad Ullah, Shahzad Latif, Shabana, Junaid Jafar, Ahmad Bilal Waqar   +6 more
doaj   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Diseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese   +10 more
doaj   +1 more source

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Clinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C, Nachega J, Mills EJ, Druyts E, Cooper CL   +4 more
doaj  

Ribavirin [PDF]

, 2020
openaire   +1 more source

Ribavirin

Infectious Diseases Newsletter, 1985
openaire   +2 more sources

Compression of Ribavirin to 35 GPa. [PDF]

Cryst Growth Des
Tiwari B, Parsons S, Giordano N.
europepmc   +1 more source

Unmasking the Threat: Acute Hepatitis E Virus Infection in a Liver Transplant Recipient. [PDF]

Case Rep Transplant
Awadallah M, Singh A, Hale GL, Yap JE, Khiew YC, Kim R, Gallegos-Orozco JF.   +6 more
europepmc   +1 more source